IBEX TECHNOLOGIES INC.
TSX : IBT

IBEX TECHNOLOGIES INC.

February 22, 2008 14:20 ET

IBEX Moves to Venture Exchange

MONTREAL, QUEBEC--(Marketwire - Feb. 22, 2008) - IBEX Technologies Inc. (TSX:IBT) announced today that it has received confirmation from the TSX Venture Exchange that IBEX will listed for trading as of Monday February 25, 2008.

IBEX shareholders will experience no interruption in their ability to trade in IBEX stock.

IBEX expects to release Q2 financial results on or about March 12, 2008.

About IBEX

The Company markets a series of proprietary enzymes (heparinases and chondroitinases) for research use, as well Heparinase I, which is used in many leading hemostasis monitoring devices.

IBEX also markets a series of arthritis assays which are widely used in pharmaceutical research. These assays are based on the discovery of a number of specific molecular biomarkers associated with collagen synthesis and degradation.

For more information, please visit the Company's web site at www.ibex.ca

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release

Safe Harbor Statement

All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or obligation to update these statements.

Contact Information

  • IBEX Technologies Inc.
    Paul Baehr
    President & CEO
    514-344-4004 (x 147)